CURRICULUM VITAE
(Downloadable PDF)

Andrew Francis Leuchter, M.D.

Academic Appointments

  • Professor, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA.  July 2000 – present.

  • Daniel X. Freedman Professor, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA.  July 2003 – June 2006.

  • Vice Chair, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA.  September 2002 – June 2006.

  • Professor, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA.  July 2000 – present.

  • Professor-in-Residence, Department of Psychiatry and Biobehavioral Sciences, UCLA Neuropsychiatric Institute, July 1999 - June 2000.

  • Director, Laboratory of Behavioral Pharmacology, UCLA Neuropsychiatric Institute, September 2002 - present.

  • Senior Research Scientist, UCLA Neuropsychiatric Institute.  September 2000 – present.

  • Director, Division of Adult Psychiatry, UCLA Department of Psychiatry and Biobehavioral Sciences; and UCLA Neuropsychiatric Institute and Hospital. January 1998 - June 2003.

  • Chief of Staff, UCLA Neuropsychiatric Hospital. July 2001 - June 2003.

  • Vice Chief of Staff, UCLA Neuropsychiatric Hospital. July 1999 - June 2001.

  • Director, Office of Professional and Community Education, UCLA Neuropsychiatric Institute. September 1995 - present.

  • Director, Quantitative Electroencephalography Laboratory, UCLA Neuropsychiatric Institute and Hospital. January 1986 - present.

  • Member, UCLA Brain Research Institute, July 1991 - present.

  • Associate Professor-in-Residence, Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine.  July 1994-July 1999.

  • Assistant Professor-in-Residence, Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine.  July 1986-July 1994.

  • Director, Clinical Core, UCLA Alzheimer’s Disease Center. September 1991 - 2000.

  • Associate Director, Geriatric Services, UCLA Neuropsychiatric Hospital. March 1995 - December 1997.

  • Co-Director, Geropsychiatry Inpatient Service, UCLA Neuropsychiatric Institute and Hospital. July 1986 - July 1992.

  • Staff Psychiatrist, Medication Development Unit, West Los Angeles VA Medical Center. July 1992 - June 1999.

 

Honors, Awards, and Recognitions

  • Award for Outstanding Research, June 1996, UCLA Research Conference on Aging. “NGF in Rats with Nucleus Basalis Lesions: Cholinergic and Quantitative Electroencephalographic Correlates,” Holschneider DP, Leuchter, AF, Walton NY, Scremin OU, Treiman DM

  • Outstanding Research Mentor Award, UCLA Department of Psychiatry & Biobehavioral Sciences, 1996

  • Early Career Research Award, American Psychiatric Electrophysiology Association, 1997

  • Fellow, American Psychiatric Association, 2000

  • Member, Mental Disorders of Aging Review Committee, National Institute of Mental Health, 1998 - 2000

  • Ad hoc grant reviewer, National Center for Complementary and Alternative Medicine, National Institutes of Health, 2003 – 2004

  • Invited presenter, “Brain Mechanisms in the Placebo Response,” Workshop sponsored by the National Institute of Mental Health and the Mind, Brain, Body, and Health Initiative.  September 27 – 28, 2004

 

Post-Graduate Training

  • Internship, Wadsworth Veterans Administration Medical Center (Medicine/Neurology) and UCLA Neuropsychiatric Institute (Geroneuropsychiatry/Neurology). July 1980-June 1981.

  • Psychiatry Resident, UCLA Neuropsychiatric Institute. July 1981-July 1984.

  • Acting Ward Director, Ward 3-South, UCLA Neuropsychiatric Institute, June 1983 - September 1983.

  • Robert Wood Johnson Clinical Scholar, UCLA Clinical Scholars Program. July 1984-June 1986.

 

Medical Education

  • BAYLOR COLLEGE OF MEDICINE, Houston, Texas, M.D., 1980

 

Undergraduate Education

  • STANFORD UNIVERSITY, Stanford, California. B.S., 1976. Interdepartmental major in biophysics

 

Board Certification

  • Diplomate, Added Qualification in Geriatric Psychiatry, American Board of Psychiatry and Neurology, 1991 and 2001

  • Diplomate, American Board of Electroencephalography and Neurophysiology, 1990

  • Diplomate in Psychiatry, American Board of Psychiatry and Neurology, 1986

 

Membership in Professional Societies

  • American Association for Geriatric Psychiatry

  • American Medical EEG Association

  • American Psychiatric Association

  • Group for the Advancement of Psychiatry

  • American Psychiatric Electrophysiology Association

  • American College of Psychiatrists

  • EEG and Clinical Neuroscience Society

 

Service to Organizations

  • Council Member-at-Large, American Medical EEG Association. 1990-1995.

  • Member, Medical and Scientific Advisory Board, Alzheimer’s Association. 1991-present

  • Chair, Physician Education Subcommittee, Alzheimer’s Association, 1992-1996

  • Member, Education Committee, Alzheimer’s Association. 1992-1999

  • Chair, Los Angeles Area Alzheimer’s Disease Biennial Conference, 1995

  • Member, Executive Committee, Sequenced Treatment Alternatives to Relieve Depression (STAR*D), December 2002 – present.

 

Editorial Service to Scholarly Publications

  • Assistant Editor, American Journal of Geriatric Psychiatry, 1993 – 2000.

  • Reviewer for Archives of General Psychiatry, American Journal of Geriatric Psychiatry, Journal of the American Psychiatric Association, JAMA, Journal of the American Geriatric Society, International Journal of Geriatric Psychiatry, Journal of Nervous and Mental Disease, Journal of Neuropsychiatry and Clinical Neurosciences, Alzheimer’s Disease: International Journal, Psychiatry Research, Biological Psychiatry, Journal of Clinical Psychiatry, and Brain.

 

University Committees

  • Member, Executive Committee, UCLA Academic Senate, September 2005 - present

  • Chair, Faculty Executive Committee, David Geffen School of Medicine at UCLA, September 2005 – present

  • Vice Chair and Chair-Elect, Faculty Executive Committee, David Geffen School of Medicine at UCLA, September 2004 – August 2005

  • Member, Faculty Executive Committee, David Geffen School of Medicine at UCLA, August 2003 – present

  • Chair, Conflict of Interest Review Committee, July 2006 – present.

  • Member, Conflict of Interest Review Committee (formerly known as the Independent Substantive Review Committee, UCLA), July 2005 – present.

  • Chair, Task Force on Prevention of Student Harassment, David Geffen School of Medicine at UCLA, December 2003 – August 2004.

  • Member, Chancellor’s Task Force on Clinical Research Process Improvement, January 2004 – July 2004.

 

Neuropsychiatric Institute and Hospital, and Department of Psychiatry and Biobehavioral Sciences Committees

  • Appointments and Advancements Committee, UCLA Department of Psychiatry and Biobehavioral Sciences, 1987-1992, 1995-1999.

  • Utilization Review Committee, NPH, 1988.

  • ECT Review Committee, NPH, 1988 - 1997

  • Mental Health Group Board of Directors, Department of Psychiatry and Biobehavioral Sciences, 1988 - 1990

  • Medical Records Committee, NPH, 1992 - 1997

  • Chair, ECT Review Committee, NPH, 1994 – 1997

  • Chair, Continuing Education Committee, NPI, 1995 – present

  • Neuropsychiatric Behavioral Health Services Board of Directors, Department of Psychiatry and Biobehavioral Sciences, 1998 – 2003

  • Steering Committee, Department of Psychiatry and Biobehavioral Sciences, 1998 – present

  • Director’s Forum, NPI, 1998 - present

  • Chair, Faculty Advisory Board, Friends of NPI, September 2003 – present

  • Chair, NPI Residency Oversight Council, January 2003 - present

 

Research Support

Public Health Service Biomedical Research Support Grant RR5756. “Psychiatric Diagnosis of Dementia.” Andrew Leuchter, M.D., Principal Investigator. November 1, 1984 - June 30, 1986. $4,870.

“Mental Illness in the Elderly: Diagnostic Testing.” 1ROl MH/NS 40705-01. Andrew Leuchter, M.D., Principal Investigator. March 1, 1986 - February 28, 1989. $151,000.

Geriatric Mental Health Academic Award. 1KO7 MH00665-01. Andrew Leuchter, M.D.,
Principal Investigator. August 1, 1986 - July 30, 1989. $161,216.

 “Early Detection of HIV Dementia.” American Foundation for AIDS Research. Andrew
Leuchter, M.D., Principal Investigator. June 1, 1988 - May 30, 1989. $60,000.

“Mental Illness in the Elderly: Diagnostic Testing.” 1RO1 MH/NS 40705-04. Andrew Leuchter, M.D., Principal Investigator. August 1, 1989 - July 31, 1995. $1,372,055.

“Research Fellowship.” R-S901019. Support for Ian Cook, M.D., for The John E. Fetzer Institute, Inc.  Andrew Leuchter, M.D., Principal Investigator. October 1, 1990 - September 30, 1991. $15,000.

“Alzheimer’s Disease Center.” AG10123-01. Jeffrey Cummings, M.D., Principal Investigator.  Andrew Leuchter, M.D., Principal Investigator, Clinical Core. September 1, 1991 - August 30, 1996. $3,520,416.

“EEG Methods for the Assessment of Cerebral Function and Dysfunction.” Investigator-initiated Collaborative Research Agreement (W920415) with Neurodata, Inc. Andrew Leuchter, M.D., Principal Investigator. September 15, 1992 - September 14, 1993. $104,000.

The Examination of Memory Processes in Elderly Adults Utilizing Quantitative Electroencephalography (qEEG)”.  Fellowship for Ruth O’Hara, Ph.D., from The Brookdale Foundation. Andrew Leuchter, M.D., Principal Investigator. May 1, 1993 - April 30, 1995. $105,000.

“Research Fellowship.”  Support for Daniel Holschneider, M.D., from American Geriatric
Society and Pfizer Inc. U.S. Pharmaceuticals Group.  Andrew Leuchter, M.D., Principal Investigator. July 1, 1994 - June 30, 1996. $80,000.

“Neurophysiologic Monitoring of Antidepressant Treatment.”  Investigator-initiated research grant from Lilly Research Laboratories. Andrew Leuchter, M.D., Principal Investigator. January 1, 1995 - April 30, 1996. $74,250.

Research Science Development Award.  “Psychiatric Assessment of Cognition in the
Elderly.” 1 K02 MH01165-01.  Andrew Leuchter, M.D., Principal Investigator.  December 1, 1994 - November 30, 1999. $494,100.

“Mental Illness in the Elderly: Diagnostic Testing.” 1 R01 MH40705-09A2.  Andrew Leuchter, M.D., Principal Investigator. September 30, 1995 - June 30, 2000. $1,969,032.

“Physiological Monitoring of Antidepressant Treatment Response.”  Investigator-initiated research grant from Wyeth-Ayerst Laboratories.  Andrew Leuchter, M.D., Principal Investigator. June 1, 1996 - December 31, 1997. $80,000.

“Alzheimer’s Disease Center.” P30 AG10123-06. Jeffrey Cummings, M.D., Principal
Investigator. Andrew Leuchter, M.D., Principal Investigator, Clinical Core. July 1, 1996 - June 30, 2001. $1,473,089.

“Therapeutic Response to Reboxetine in Major Depression: Relationship to Pretreatment Cordance.”  Investigator-initiated research grant from Pharmacia & Upjohn. Andrew Leuchter, M.D., Principal Investigator. November 1999 - April 2002.  $282,346.

“Open Label Reboxetine Continuation Therapy.”  Investigator-initiated research grant from Pharmacia & Upjohn.  Andrew Leuchter, M.D., Principal Investigator.  January 1999 - February 2002. $99,323.

Research Science Development Award.  “Enhancing Treatment Outcomes in Depression.”
1 K02 MH01165-06. Andrew Leuchter, M.D., Principal Investigator. December 1999 - November 2004.  $670,950.

“Research Training. Psychobiological Sciences.”  T32 MH17140. Andrew Leuchter, M.D., Principal Investigator. July 1, 2003 - June 30, 2008.  $1,414,704.

“Physiologic Monitoring of Antidepressant Medication Effects in Normal Control Subjects.”  Investigator-initiated research grant from Lilly Research Laboratories.  Andrew Leuchter, M.D., Principal Investigator.  December 1, 2000 – November 30, 2003.  $122,880.

“Sequenced Treatment Alternatives to Relieve Depression”  Subcontract from University of Texas Southwestern/NIMH.  Andrew Leuchter, M.D., Regional Center Director.  April 1, 2001 – September 30, 2004.  $466,054.

“A Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Efficacy of MK-0869 in the Maintenance of Antidepressant Effect in Geriatric Outpatients with Major Depressive Disorder.”  Research contract from Merck & Company.  Andrew Leuchter, M.D., Principal Investigator.  May 2002 – February 2004.  $295,100.

“Open-Label Treatment w/Duloxetine HCl Once-Daily Dosing for Evaluation of Stabilization Dose in Patients with Major Depression.”  Research contract from Eli Lilly & Company.  Andrew Leuchter, M.D., Principal Investigator. December 2002 – December 03, 2005.  $141,417.

“Placebo Responder Evaluation using Comprehensive Investigation of Symptoms
and EEG (PRECISE).”  Investigator-initiated research grant from Pfizer Global Medical Research (Biomarkers Development) and Lilly Research Laboratories.  Andrew Leuchter, M.D., Principal Investigator.  December 23, 2003 – June 30, 2006.  $570,052.

“Psychobiologic Factors of the Placebo Response in MDD”.  1 RO1 AT002479-01. Andrew Leuchter, M.D., Principal Investigator.  September 29, 2004 – June 30, 2008.  $1,000,000.

“Depression Treatment Network.”  Subcontract from University of Texas Southwestern/NIMH.  Andrew Leuchter, M.D., Regional Center Director.  September 29, 2004 – September 28, 2006.  $160,700.

“Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome” Industry-initiated research grant from Eli Lilly and Company. Andrew F. Leuchter, M.D., Principal Investigator. October 01, 2005 – April 12, 2007.  $174,435.

“Examination of Quantitative Electroencephalographic Biomarkers in Huntington’s Disease: A Pilot Project.”  20063027 Investigator-initiated research contract from High Q Foundation, Andrew F. Leuchter, M.D., Principal Investigator. September 01, 2006 – August 31, 2007.  $63,048.

“An 8-week, randomized, double-blind, fixed dosage, placebo controlled, parallel-group, multi-center study of the efficacy, safety and tolerability of agomelatine 25 mg and 50 mg in the treatment of Major Depressive Disorder (MDD) followed by a 52-week, open-label extension (CAGO178A2302E).”  Multi-site industry sponsored research contract with Novartis Pharmaceuticals. Andrew F. Leuchter, M.D., Principal Investigator. November 01, 2006 – October 31, 2007.  $246,916.

 
Patents

  1. U.S. Patent:  Diagnosing brain conditions by quantitative electroencephalography. Inventors: Leuchter AF, Cook IA. U.S. Patent Number 5,230,346.

  2. U.S. Patent:  Determining the nature of brain lesions by electroencephalography. Inventors: Leuchter AF, Cook IA. U.S. Patent Number 5,269,315.

  3. U.S. Patent:  Method and apparatus for determining the nature of brain lesions by electroencephalography. Inventors: Leuchter AF, Cook IA. U.S. Patent Number 5,309,923.

 

Articles

  1. Leuchter AF: The responsibilities for the state for the prevention and treatment of mental illness among prisoners. Journal of Forensic Sciences   26:134, 1981.

  2. Leuchter AF, Spar JE: The late-onset psychoses: clinical and diagnostic features. Journal of Nervous and Mental Disease 173(8): 488, 1985.

  3. Leuchter AF, Spar JE, Walter DO, and Weiner H: Electroencephalographic spectra and coherence in the diagnosis of Alzheimer’s-type and multi-infarct dementia: a pilot study. Archives of General Psychiatry 44(11): 993-998, 1987.

  4. Leuchter AF and Walter DO: Topography of brain electrical activity in Alzheimer’s disease. Bulletin of Clinical Neurosciences 53:78-83, 1988.

  5. Leuchter AF and Walter DO: Diagnosis and assessment of dementia using functional brain imaging.  International Psychogeriatrics 1:63-72, 1989.

  6. Leuchter AF, Read S, Walter DO, Shapira J, and Smith C: Stable bimodal response to cholinomimetic drugs in Alzheimer’s disease: brain mapping correlates. Neuropsychopharmacology 4:165-173, 1991.

  7. Leuchter AF, Jacobson SA: Quantitative measurement of brain electrical activity in delirium. International Psychogeriatrics 3:231-247, 1991.

  8. Leuchter AF, Newton TF, Cook IA, Walter DO, Rosenberg-Thompson S, Lachenbruch PA: Changes in brain functional connectivity in Alzheimer’s-type and infarct dementia. Brain 115:1543-1561, 1992.

  9. Newton TF, Leuchter AF, Walter DO, Van Gorp W, Stern C, Mandelkern M, Weiner H: EEG coherence in men with AIDS: association with subcortical metabolic activity. Journal of Neuropsychiatry and Clinical Neurosciences 5(3): 316-321, 1993.

  10. Jacobson S, Leuchter AF, Walter D: Conventional and quantitative EEG in the diagnosis of delirium among the elderly. Journal of Neurology, Neurosurgery and Psychiatry 56:153-158, 1993.

  11. Small GW, Leuchter AF, Mandelkern MA, LaRue A, Okonek A, Lufkin RB, Jarvik LF, Matsuyama SS, Bondareff W: Clinical, neuroimaging, and environmental risk differences in monozygotic female twins appearing discordant for dementia of the Alzheimer type. Archives of Neurology 50:209-219, 1993.

  12. Leuchter AF, Daly KA, Rosenberg-Thompson S, Abrams M: The prevalence of electroencephalographic abnormalities among patients with possible organic mental syndromes. Journal of the American Geriatric Society 41:605-611, 1993.

  13. Jacobson S, Leuchter AF, Walter DO, Weiner H: Serial quantitative EEG among elderly subjects with delirium. Biological Psychiatry 34:135-140, 1993.

  14. Leuchter AF, Cook IA, Newton TF, Walter DO, Rosenberg-Thompson S, Lachenbruch PA, Weiner H: Regional differences in brain electrical activity in dementia: use of spectral power and spectral ratio measures.  Electroencephalography and Clinical Neurophysiology 87:385-389, 1993.

  15. Newton TF, Leuchter AF, Miller EM, Weiner H: Quantitative EEG in patients with AIDS and asymptotic HIV infection. Clinical EEG 25:18-25, 1994.

  16. Dunkin JJ, Leuchter AF, Newton T, Cook, IA: Reduced EEG coherence in dementia: state or trait marker? Biological Psychiatry 35:870-879, 1994.

  17. Leuchter AF, Cook IA, Lufkin RB, Dunkin J, Newton TF, Cummings JL, Mackey K, Walter D: Cordance: A new method for assessment of cerebral perfusion and metabolism using quantitative electroencephalography. Neuroimage 1:208-219, 1994.

  18. Leuchter AF, Dunkin J, Lufkin R, Anzai Y, Newton T: The effect of white-matter disease on functional connections in the aging brain.  Journal of Neurology, Neurosurgery and Psychiatry 57:1347-1354, 1994.

  19. Leuchter AF, Cook IA, Mena I, Dunkin J, Cummings JL, Newton, T, Migneco O, Lufkin R, Walter D, Lachenbruch P: Assessment of cerebral perfusion using quantitative EEG cordance. Psychiatry Research: Neuroimaging 55:141-152, 1994.

  20. Leuchter AF, Simon SL, Daly KA, Rosenberg-Thompson S, Abrams M, Dunkin JJ, Cook IA, Newton TF, Walter DO, Cummings JL: Quantitative EEG correlates of outcome in elderly psychiatric patients. I. Cross-sectional and longitudinal assessment of patients with dementia. American Journal of Geriatric Psychiatry 2:200-209, 1994.

  21. Leuchter AF, Simon SL, Daly KA, Abrams M, Rosenberg-Thompson S, Dunkin JJ, Cook IA, Newton TF, Spar JE: Quantitative EEG correlates of outcome in elderly psychiatric patients. II. Two–year follow-up of patients with depression.  American Journal of Geriatric Psychiatry 2:290-299, 1994.

  22. Newton TF, Leuchter AF, Walter D, Van Gorp W, Morgenstern H, Miller E, Lieb K, Visscher B, Satz P, Weiner H: Electroencephalographic coherence in acquired immune deficiency syndrome. Psychiatry Research 54:1-11, 1994.

  23. Dunkin JJ, Osato S, Leuchter AF: Relationships between EEG coherence and neuropsychological test in dementia. Clinical EEG 26(1):47-59, 1995.

  24. Holschneider D, Leuchter AF: Beta activity in aging and dementia.  Brain Topography 8(2):169-180, 1995.

  25. Cook IA, Leuchter AF: Synaptic dysfunction in Alzheimer’s disease: clinical assessment using quantitative EEG. Brain and Behavioral Research 78: 15-23, 1996.

  26. Yener GG, Leuchter AF, Jenden D, Read SL, Cummings JL, Miller BL. Quantitative EEG in fronto-temporal dementias. Clinical EEG 27(2):61-68, 1996.

  27. Holschneider DP, Leuchter AF, Uijtdehaage SH, Abrams M, Rosenberg-Thompson S. Loss of High-frequency EEG response to thiopental in Alzheimer’s dementia. Neuropsychopharmacology, 20:1-7, 1997.

  28. Leuchter AF, Cook IA, Uijtdehaage SH, Lufkin RB, Anderson-Hanley C, Abrams M, Rosenberg-Thompson S, O’Hara R, Simon SL, Babaie AB. Brain structure and function, and the outcomes of treatment for depression. Journal of Clinical Psychiatry 55[suppl 16]:22-31, 1997.

  29. Newton TF, Leuchter AF. EEG power correlates with subcortical metabolic activity in AIDS. Journal of Neuropsychiatry and Clinical Neurosciences 9:974-978, 1997.

  30. Holschneider DP, Leuchter AF, Walton NY, Scremin OU, Treiman DM. Changes in cortical EEG and cholinergic function in response to NGF in rats with nucleus basalis lesions. Brain Research 765:228-237, 1997.

  31. Cook IA, Leuchter AF, Uijtdehaage SH, Holschneider D, Osato S, Abrams M, Rosenberg-Thomson S. Altered cerebral energy utilization in late life depression. Journal of Affective Disorders 49(2): 89-99, 1998.

  32. Holschneider DP, Leuchter AF, Scremin OU, Treiman DM, Walton NY. Changes in brain electrical coherence in response to NGF in rats with nucleus basalis lesions. Brain Research Bulletin, 45:531-541, 1998.

  33. Cook IA, O’Hara R, Uijtdehaage SH, Mandelkern M, Leuchter AF. Assessing the accuracy of topographic EEG mapping for determining local brain function. EEG Clin Neurophys 107:408-414, 1998.

  34. Leuchter AF, Uijtdehaage SH, Cook IA, O’Hara R, Mandelkern M. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Research: Neuroimaging 90:125-140, 1999.

  35. Cook IA, Leuchter AF, Witte E, Abrams M, Uijtdehaage SHJ, Stubbeman W, Rosenberg-Thompson S, Anderson-Hanley C. Neurophysiologic predictors of treatment response to fluoxetine in major depression. Psychiatry Research 85:263-273, 1999.

  36. Dunkin JJ, Leuchter AF, Cook IA, Kasl-Godley JE, Abrams M, Rosenberg-Thompson S. Executive dysfunction predicts non-response to fluoxetine in major depression. Journal of Affective Disorders 60:13-23, 2000.

  37. Holschneider DP, Waite JJ, Leuchter AF, Walton NY, Scremin OU. Changes in electrocortical power coherence in response to the cholinergic toxin 192 IgG-saporin. Experimental Brain Research 126:270-280, 1999.

  38. Holschneider DP, Leuchter AF.  Attenuation of brain high frequency electrocortical response after thiopental in early stages of Alzheimer's dementia. Psychopharmacology 149:6-11, 2000.

  39. Edwards-Lee T, Cook IA, Fairbanks L, Leuchter AF, Cummings JL. Quantitative electroencephalographic correlates of psychosis in Alzheimer Disease.  Neuropsychiatry, Neuropsychology, and Behavioral Neurology13: 163-170, 2000.

  40. Cook IA, Leuchter AF.  Prefrontal changes and treatment response prediction in depression.   Seminars in Clinical Neuropsychiatry 6:113-120, 2001

  41. Leuchter, AF, Cook IA, Witte EA, Morgan ML, Abrams, M.  Changes in brain function of depressed subjects during treatment with placebo.  American Journal of Psychiatry 159: 122-129, 2002.

  42. Cook IA, Morgan ML, Dunkin JJ, David S, Witte E, Lufkin R, Abrams M, Rosenberg S, Leuchter A.  Estrogen replacement therapy is associated with less progression of subclinical structural brain disease in normal elderly women: A pilot study.  International Journal of Geriatric Psychiatry 17: 610-618, 2002.

  43. Cook IA, Leuchter AF, Witte EA, Stubbeman WF, Abrams M, Rosenberg S.  Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 27:120-131, 2002.

  44. Cook IA, Leuchter AF, Morgan M, Witte EA, David S, Lufkin R, Babaie A, Dunkin J, O’Hara R, Simon S, Lightner A, Thomas S, Broumandi D, Badjatia N, Mickes L, Mody R, Arroyo S, Zheng Z, Abrams M, Rosenberg S.  Cognitive and physiologic correlates of subclinical structural brain disease in elderly normal controls.  Archives of Neurology 59: 1612-1620, 2002.

  45. Newton TF, Cook IA, Kalechstein AD, Duran S, Monroy F, Ling W, Leuchter AF.  Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals.  Clinical Neurophysiology 114: 410-415, 2003

  46. Cook IA, Leuchter AF, Morgan ML, Dunkin JJ, Witte E, David S, Mickes L, O'Hara R, Simon S, Lufkin R, Abrams M, Rosenberg S. Longitudinal progression of subclinical structural brain disease in normal aging.  American Journal of Geriatric Psychiatry 12: 190-201, 2004.

  47. Newton TF, Kalechstein AD, Hardy DJ, Cook IA, Nestor L, Ling W, Leuchter AF.  Association between quantitative EEG and neurocognition in methamphetamine dependent volunteers. Clinical Neurophysiology 115: 194-198, 2004.

  48. Leuchter AF, Morgan ML, Cook IA, Dunkin JJ, Abrams M, Witte EA. Pretreatment neurophysiologic and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacology (Berl) published on-line 2004 July 14. 

  49. Marie-Mitchell A., Leuchter AF, Chou C, Gauderman WJ, Azen SP.  Predictors of treatment outcome in antidepressant clinical trials. Psychiatry Research 127: 73-84, 2004.

  50. Krell HV, Leuchter AF, Morgan M, Cook IA, Abrams M.  Subject expectations and outcome of treatment with an experimental antidepressant.  The Journal of Clinical Psychiatry 65: 1174-1179, 2004.

  51. Stubbeman, WF, Leuchter AF, Cook IA, Shurman BD, Gunay I, Gonzalez S.  Neurophysiologic prediction of ECT response in depression.  Journal of ECT 20: 142-144, 2004.

  52. Morgan ML, Witte EA, Cook IA, Leuchter AF, Abrams M, Siegman B.  Influence of Age, gender, health status, and depression on quantitative EEG.  Neuropsychobiology 52: 71-76, 2005.

  53. Cook IA, Leuchter AF, Morgan ML, Stubbeman WF, Siegman B, Abrams M.  Changes in prefrontal activity characterize clinical response in treatment resistant depression.  Journal of Psychiatric Research 39: 461-466, 2005. Abstract

  54. Hunter AM, Leuchter AF, Morgan M, Cook IA, Abrams M, Siegman B, DeBrota D, Potter WZ.  Changes in brain function associated with side effects in normal subjects randomized to venlafaxine or placebo.  Neuropsychopharmacology 30: 792 –799, 2005. Abstract

  55. Krell HV, Leuchter AF, Cook IA, Abrams M.  Evaluation of reboxetine, a noradrenergic antidepressant on the treatment of fibromyalgia and chronic low back pain.  Psychosomatics 47: 1-6, 2005. Abstract

  56. Morgan ML, Cook IA, Rapkin AJ, VanBatenburg C, Leuchter AF.  Estrogen augmentation in perimenopausal depression: a pilot study. Journal of Clinical Psychiatry 66: 774-780, 2005. Abstract

  57. Lesser IM, Leuchter AF, Trivedi MH, Davis LL, Wisniewski S, Petersen T, Stegman D, Rush AJ.  Characteristics of insured and non-insured depressed outpatients:  preliminary findings from STAR*D.  Psychiatric Services 56: 995-1004, 2005. Abstract

  58. Moses T, Leuchter AF, Cook IA, Abrams M.  Does the clinical course of depression determine improvement in symptoms and quality of life? Journal of Nervous and Mental Disease 194(4):241-8, 2006. Abstract

  59. Venneman S, Leuchter AF, Bartzokis G, Beckson M, Simon SL, Schaeffer M, Rawson R, Newton T, Cook IA, Uijtdehaage SHJ, Ling W. Variation in neurophysiological function and evidence of quantitative electroencephalogram discordance: predicting cocaine-dependent treatment attrition. The Journal of Neuropsychiatry and Clinical Neurosciences 18(2):208-16, 2006. Abstract

  60. Morgan ML, Cook IA, Rapkin AJ, Leuchter AF. Neurophysiologic changes during estrogen augmentation in perimenopausal depression. Maturitas 56(1):54-60, 2007. Abstract

  61. Hunter AM, Leuchter AF, Morgan ML, Cook IA. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. The American Journal of Psychiatry 163(8):1426-32, 2006. Abstract

  62. Claassen CA, Trivedi MH, Rush JA, Husain MM, Zisook S, Young E, Leuchter AF, Wisniewski SR, Balasubramani GK, Alpert J. Clinical differences among depressed patients with and without a history of suicide attempts: findings from the STAR*D trial. Journal of Affective Disorders 97:77-84, 2007. Abstract

  63. Cook IA, Bookheimer SY, Mickes L, Leuchter AF, Kumar A. Aging and brain activation with working memory tasks: an fMRI study of connectivity. International Journal of Geriatric Psychiatry 22(4):332-42, 2007. Abstract

  64. Shapiro D, Cook IA, Davydov DM, Ottaviani C, Leuchter AF, Abrams M. Yoga as a Complementary Treatment of Depression: Effects of Traits and Moods on Treatment Outcome. Evidence Based Complementary and Alternative Medicine. 2007 Feb 28 [epub ahead of print] Abstract

  65. Hunter AM, Cook IA, Leuchter AF. The Promise of the Quantitative Electroencephalogram as a Predictor of Antidepressant Treatment Outcomes in Major Depressive Disorder. Psychiatr Clin North Am 30(1):105-124, 2007. Abstract

  66. Beck TS, Leuchter AF. Diagnostic criteria for Creutzfeldt-Jacob Disease: A retrospective study in a psychiatric hospital. Psychiatry and Clinical Neurosciences. (in press)

  67. Lesser IM, Leuchter AF, Trivedi MH, Davis LL, Wisniewski SR, Balasubramani GK, Fava M, Rush AJ. Insured and non-insured depressed outpatients: how do they compare? Annals of Clinical Psychiatry. (in press)

  68. Cook IA, Stubbeman WF, Witte EA, Abrams M, Shurman B, Venneman S, Rosenberg-Thompson S, Leuchter, AF. Quantitative EEG features characterize the durability of SSRI response in mood disorders: a pilot study. (in submission)

  69. Leuchter AF, Simon SL, Newton TF, Baxter LR: Quantitative electroencephalography in obsessive-compulsive disorder: regional and inter-regional measures. (in submission)

  70. Cook IA, Leuchter AF, Greenwald SD, Morgan ML, Hanson KG, Siegman B, Abrams M, Johnstone J. Single-channel EEG bispectrum is associated with antidepressant treatment response. (in submission)

  71. Muthén B, Leuchter AF, Morgan ML, Cook IA. Assessing medication effects in the presence of placebo response: A clinical trial application of growth mixture modeling. (in submission)

  72. Leuchter AF, Cook IA, DeBrota, DJ, Hunter AM, Potter WZ, McGrouther CC, Morgan ML, Abrams MA, Siegman B. Changes in Brain Function During Administration of Venlafaxine or Placebo to Normal Subjects. (in submission)

  73. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, Biggs MM, Zisook S, Leuchter AF, Howland R, Warden D, Trivedi MH. Do Outpatients with Anxious vs. Non-Anxious Major Depressive Disorder Have Different Treatment Outcomes? A STAR*D Report. (in submission)

 

Monographs

Leuchter AF, Reynolds CF, Katz IR, Alexopoulos GS, Lebowitz BD: Late-Life
Depression: Recent Advances in Assessment and Treatment. Proceedings of a symposium held at the Institute on Psychiatric Services meeting in Boston, MA on October 8, 1995.

Leuchter AF, Bruce ML, Frazer A, Roose SP, Borson S: Medication Treatment
Outcomes in Geriatric Depression: Does Mechanism of Action Make a Difference? CME clinical symposium update from the 1999 American Association for Geriatric Psychiatry Annual Meeting in New Orleans, LA on March 14-17, 1999.

Editor-in-Chief: Minds & Medicine: The Role of New Antipsychotics in the Treatment of Bipolar Disorder. Convened at the American College of Neuropsychopharmacology in San Juan, Puerto Rico on December 08, 2003.

Editor-in-Chief: Minds & Medicine: Impact of Atypical Antipsychotics on Functional Recovery and Long-term Outcomes. Convened at the American Psychiatric Association Annual Meeting in New York, New York on May 05, 2004.

Editor-in-Chief: Minds & Medicine: Managing Antipsychotic-related Metabolic Effects in Individuals with Mental Illness. Convened at the American College of Neurospychopharmacology Annual Meeting in San Juan, Puerto Rico on December 14, 2004.

Editor-in-Chief: Minds & Medicine: Treatment Advances in Chronic Neuropathic Pain. Proceedings from the UCLA Minds & Medicine Editorial Meeting in Palm Springs, California on February 24, 2005.

 

Book Chapters

  1. Leuchter AF, Jarvik LF. Drug treatment of dementia. In Burrows GD (ed.), Anticonvulsants, and Other Drugs in Psychiatry, vol. 4. Amsterdam: Elsevier, pp. 371-384, 1987.

  2. Leuchter AF, Garcia M. Neuroimaging in the elderly with chronic mental illness. In Light E, Lebowitz B (eds.), The Chronic Mentally Ill Elderly: Directions for Research. Washington, DC: American Psychiatric Press, pp. 145-166, 1991.

  3. Leuchter AF. Electroencephalography. In Sadavoy J, Lazarus L, Jarvik L (eds.), Comprehensive review of Geriatric Psychiatry. Washington, DC: American Psychiatric Press, pp. 273-283, 1991.

  4. Leuchter AF. Brain structural and functional correlates of late-life depression. In Lebowitz B, Schneider L (eds.), Diagnosis and Treatment of Depression in Late-Life. Washington, DC: American Psychiatric Press, pp. 117-130, 1994.

  5. Leuchter AF, Holschneider D. Quantitative electroencephalography: neurophysiological alterations in normal aging and geriatric neuropsychiatric disorders. In Coffey E, Cummings J (eds.), Textbook of Geriatric Neuropsychiatry. Washington, DC: American Psychiatric Press, pp. 215-240, 1994.

  6. Cook IA, Leuchter AF. Structural and functional brain disturbances in geriatric depression. In Finkel SI, Bergener M (eds.), Treating Alzheimer’s and Other Dementias: Clinical Applications of Recent Research Advances. New York: Springer Publishing Co., pp.358-369, 1995.

  7. Leuchter AF, Daly K. Treatment of psychosis. In Samiy AH (ed.), Textbook of Therapeutic Medicine for Practicing Physicians (in press).

  8. Leuchter AF. Geriatric psychiatry: neuroimaging. In Kaplan HI, Sadock BJ (eds.), Comprehensive Textbook of Psychiatry, VI. Baltimore: Williams & Wilkins Company, 1995.

  9. Jacobson SA, Leuchter AF. Delirium. In Reichman WE, Katz PR (eds.),  Psychiatric Care in the Nursing Home. New York: Oxford University Press, 1996.

  10. Leuchter AF, Holschneider D. Electroencephalography. In Sadavoy J, Lazarus L, Jarvik L (eds.), Comprehensive Review of Geriatric Psychiatry-II. Washington, DC: American Psychiatric Press, 1996.

  11. Leuchter, AF. Indications for neuroimaging. In Ames D, Chui E (eds.),  Neuroimaging and the Psychiatry of Late Life. New York: Cambridge University Press, 1997.

  12. Leuchter AF, Cook IA. Electroencephalography and magnetoencephalography. In Ames D, Chui E (eds.), Neuroimaging and the Psychiatry of Late Life. New York: Cambridge University Press, 1997.

  13. Walter DO, Leuchter AF. A tutorial on classical computer analysis of EEGs: spectra and coherences. In Butler S, Angeleri F, Giaquinto S, Majkowski J (eds.), Analysis of the Electrical Activity of the Brain. New York: John Wiley & Sons, Ltd, 1997.

  14. Leuchter AF, Holschneider D. Quantitative electroencephalography: neurophysiological alterations in normal aging and geriatric neuropsychiatric disorders. In Coffey E, Cummings J (eds.), Textbook of Geriatric Neuropsychiatry, 2nd Edition. Washington DC: American Psychiatric Press, 1999.

  15. Leuchter AF, Holschneider D. Electroencephalography. In Sadavoy J, Lazarus L, Jarvik L (eds.), Comprehensive Review of Geriatric Psychiatry- 3rd Edition. Washington, DC: American Psychiatric Press, 2004.

Brief Reports  and Book Reviews

  1.       Leuchter AF: Getting ahead in science. Contemporary Psychiatry. 2:138, 1983.

  2.       Leuchter AF: Practical geriatrics: assessment and treatment of the late-onset psychoses.  Hospital  and Community Psychiatry. 36(8):815, 1985.

  3.       Leuchter AF: Late-onset psychoses: differential diagnosis and management. Geriatric Medicine Today. 7:121-129, 1988.

  4.       Szuba M, Leuchter AF: Falling backwards in two elderly patients taking bupropion. Journal of Clinical Psychiatry. 53:157-159, 1992.

  5.       Bystritsky A, Leuchter A, Vapnik T. EEG abnormalities in non-medicated panic disorder. Journal of Nervous and Mental Disease. 187(2):113-4, 1999.

 

Abstracts

  1. Wallick E, Ray V, Anner B, Leuchter A, and Schwartz A: H³-ouabain binding to highly purified Na+, K+-ATPase. Federation Proceedings 34:249, 1975.

  2. Wallick E, Ray V, Leuchter A, and Schwartz A: Chemical modification of purified Na+, K+-ATPase. Federation Proceedings. 35:1663, 1976.

  3. Leuchter AF, Walter DO, Weiner H: Differential diagnosis of dementia using topographic electroencephalography. Journal of Clinical Neurophysiology. 5:328, 1988.

  4. Leuchter AF, Read S, Shapira J, Walter D, Smith C: Computer-analyzed  EEG and treatment of Alzheimer’s disease. New Research Program & Abstracts, American Psychiatric Associated 141st Annual Meeting. P. 63, 1988.

  5. Daly K, Leuchter AF, Rosenberg-Thompson S: The usefulness of electroencephalography in diagnosis of dementia early in the course of illness. Abstract presented at Southern California Regional Meeting. Los Angeles, CA, February 1989.

  6. Leuchter AF, Newton TF, Van Gorp W, Miller E, Weiner H, Freeman D, Evan G, Satz P: Early detection of HIV-effects on brain function. New Research Program and Abstracts, American Psychiatric Associations 142nd Annual Meeting. P. 171, 1989.

  7. Newton TF, Leuchter AF, Walter DO, Lieb K, Weiner H: EEG coherence in AIDS. American Electroencephalographic Society 1990 Annual Meeting and Courses Program. P. 26, 1990.

  8. Newton TF, Leuchter AF, Walter DO, Van Gorp W, Stern C, Mandelkern M, Weiner H: EEG coherence in men with AIDS: association with subcortical metabolic
    activity. Abstract presented at NIMH training program in HIV disease.
    Washington, D.C. March 1991.

  9. Mackey JK, Leuchter AF, Cook IA, Lufkin RB, Duerinckx AJ, Walter DO: Lesions on MRI in patients with dementia: correlation with brain functional abnormalities seen in quantitative. EEG Society for Magnetic Resonance Imaging, Chicago, IL, April 31, 1991.

  10. Leuchter AF, Lufkin RB, Cook IA, Cummings JL, Ross GW, Mackey K: Electrophysiologic detection of deep white-matter ischemic disease in the elderly. Book of Abstracts, Proceedings of the Fifth Congress of the International Psychogeriatic Association. P. 27, 1991.

  11. Leuchter AF, Cook IA, Lufkin RB, Walter DO, Mena I, Miller BL: Quantitative EEG, PET, and SPECT in brain disease. 1992 CME Syllabus & Proceedings Summary, American Psychiatric Association, 145th Annual Meeting. P.103,Washington, D.C., May 2-7, 1992.

  12. Newton TF, Leuchter AF, Cook IA, Walter DO: Quantitative EEG coherence and subcortical dysfunction in AIDS. 1992 CME Syllabus & Proceedings Summary, American Psychiatric Association, 145th Annual Meeting. P.258, 1992.

  13. Jacobson SA, Leuchter AF: Serial EEG and quantitative EEG in delirium. 1992 CME Syllabus & Proceedings Summary, American Psychiatric Association, 145th Annual Meeting. P.259, 1992.

  14. Leuchter AF, Cook IA, Mena I, Dunkin J, Newton TF, Lufkin RB, Mackey, Walter DO, Cummings JL, Lachenbruch P: A new method for assessment of cerebral perfusion and metabolism. American Electroencephalographic Society 1992 Annual Meeting and Courses Program. P.96, 1992.

  15. Newton TF, Leuchter AF, Cook IA, Walter DO, Dunkin J, Lachenbruch P: Dementia as syndrome of cortical disconnection. American Electroencephalographic Society 1992 Annual Meeting and Courses Program. 1992.

  16. Cook IA, Leuchter AF, O’Hara R, Newton TF, Walter DO: Assessment of cognitive processes using EEG. American Electroencephalographic Society 1992 Annual Meeting and Courses Program. 1992.

  17. Dunkin JJ, Leuchter AF, Cook IA, Newton TF, Rosenberg-Thompson S: Longitudinal changes in EEG power and coherence in normal and abnormal aging: relationship to mental status changes. Journal of Clinical and Experimental Neuropsychology. Vol. 15, p.31, 1993.

  18. Leuchter A, Newton T, Cook I, Dunkin J, Holschneider D, Lufkin R, Mena I: Neuroimaging findings in normal and pathologic aging. Abstract presented at the Sixth Congress of the International Psychogeriatric Association. Berlin, Germany, September 5-10, 1993.

  19. Leuchter A, Cook I: Quantitative electroencephalography as a measure of synaptic plasticity in dementia. First International Conference on Synaptic Plasticity. Freiburg, Germany, October 1994.

  20. Newton TF, Leuchter AF, Cook IA, Beckson M, Uijtdehaage S, Simon SL, Goldman M, Londholm J, Santiago I, Ling W: Acute cocaine administration reverses EEG signs of cocaine withdrawal. Problems of Drug Dependence 1995: Proceedings of the 57th Annual Scientific Meeting. The College on Problems of Drug Dependence, Inc. National Institute on Drug Abuse Research Monograph Series, No. 162, p.142, 1995.

  21. Leuchter AF, Uijtdehaage SH, O’Hara R, Cook IA, Mandelkern M, Newton TF, Ling W: Validation of a non-invasive method for monitoring drug effects in clinical trials. Abstracts of the College on Problems of Drug Dependence 58th Annual Scientific Meeting, June 22-27, 1996, p. 80, 1996.

  22. Leuchter AF, Cook IA, Uijtdehaage SH, Lufkin RB, Abrams M, Rosenberg-Thompson S: Brain function and the outcomes of treatment for depression. Abstracts of the X World congress of Psychiatry, Madrid, August 23-28, 1996, Volume 1, p.80, 1996.

  23. Holschneider DP, Leuchter AF, Walton NY, Scremin OU, Treiman DM: NGF infusions in rats with Nucleus basalis lesions: quantitative electroencephalographic and cholinergic correlates of recovering brain function. Abstract presented at annual meeting of the American Geriatric Society, Chicago, IL, May 4, 1996.

  24. Leuchter AF, Cook IA, Uijtdehaage SH, O’Hara R, Mandelkern M: Non-invasive monitoring of brain function. Abstract presented at the American Psychiatric Association Annual Meeting. San Diego, California, May 17-22, 1997.

  25. Leuchter AF, Cook IA, Uijtdehaage SH, Dunkin J, Anderson-Hanley C, Abrams M, Rosenberg-Thompson S: Neurophysiologic prediction of antidepressant treatment response. Poster presented at the NCDEU Annual Meeting. Boca Raton, Florida, May 29-30, 1997.

  26. Leuchter AF, Uijtdehaage SHJ, Simon SL, Rawon R, Ling W: QEEG cordance detects changes in brain function among methamphetamine abusers. Abstract presented at the fifty-ninth annual CPDD meeting in Nashville, TN, June 14-19, 1997.

  27. Dunkin JJ, Cook IA, Leuchter AF, Kasl-Godley JE, Abrams M, Betz B, Anderson-Hanley C: Executive dysfunction predicts non-response to fluoxetine in major depression. Journal of the International Neurological Society 4:5, 1997.

  28. Holschneider DP, Leuchter AF, Abrams M, Rosenberg-Thompson S: Attenuation of brain high frequency response after thiopental in early stages of Alzheimer’s dementia. Abstract presented at annual meeting of the American Association for Geriatric Psychiatry, San Diego, CA March 10, 1988.

  29. Leuchter AF, Cook IA, Rosenberg-Thompson S, Abrams M, Uijtdehaage SHJ, Anderson-Hanley C, Dunkin J. Differential therapeutic responses in depression. Abstract presented at a symposium, “Predicting Outcomes of Antidepressant Treatment “ at the American Psychiatric Association Annual Meeting, Toronto, Canada, May 30-June 4, 1998.

  30. Cook IA, Leuchter AF, Uijtdehaage SHJ, Abrams M, Anderson-Hanley C, Rosenberg-Thompson S, Dunkin J: Neurophysiologic predictors of treatment response. Abstract presented at a symposium, “Predicting Outcomes of Antidepressant Treatment” at the American Psychiatric Association Annual Meeting, Toronto, Canada, May 30-June 4, 1998.

  31. Leuchter AF, Cook IA, Witte E, Abrams M, Anderson-Hanley C, Rosenberg-Thompson S, Uijtdehaage SHJ, Dunkin J. Predictors of differential response to antidepressant medication. Abstract presented at the 1998 Annual Meeting of the American Psychiatric Electrophysiology Association, Toronto, Canada, May 30-31, 1998.

  32. Leuchter AF, Bartzokis G, Venneman S, Beckson M, Wilkins J, Schaeffer M, Ling W: Neurophysiologic predictors of successful completion of a cocaine treatment trial. Poster presented at the sixtieth annual CPDD meeting in Scottsdale, Arizona, June 13-18, 1998.

  33. Leuchter AF, Bartzokis G, Venneman S, Beckson M, Wilkins J, Schaeffer M, Rawson R, Ling W: Neurophysiologic predictors of subject retention in a cocaine treatment trial. Poster presented at the NCDEU Annual meeting. Boca Raton, Florida, June 10-13, 1998.

  34. Cook IA, Stubbeman WF, Witte E, Leuchter AF:  Neurophysiologic Measures and Treatment Response in Depression.  Presented at the West Coast College of Biological Psychiatry Annual Meeting, San Diego, CA, April 14, 2000.

  35. Cook IA, Leuchter AF, Witte E, Stubbeman WF:  Prefrontal changes predict speed and completeness of antidepressant response:  Poster presented at the New Research session, American Psychiatric Association Annual Meeting, Chicago, IL, May 15 - 17, 2000.

  36. Stubbeman WF, Leuchter AF, Cook IA, Shurman B, Gunay I, Gonzalez S:  Neurophysiologic prediction of ECT response in depression.  Poster presented at the New Research session, American Psychiatric Association Annual Meeting, Chicago, Illinois, May 15 - 17, 2000.

  37. Leuchter AF, Cook IA, Witte EA, Abrams M:  Brain Functional and Structural Differences between Medication and Placebo Responders.  Poster presented at the NCDEU Annual meeting.  Boca Raton, Florida, May 29-31, 2000.

  38. Cook IA, Leuchter AF, Witte E, Stubbeman WF:  Prefrontal changes predict speed and completeness of antidepressant response. Poster presented at the NCDEU Annual Meeting. Boca Raton, Florida, May 29 - June 1, 2000.

  39. Stubbeman WF, Leuchter AF, Cook IA, Shurman B, Gunay I, Gonzalez S:  Neurophysiologic prediction of ECT response in depression.  Poster presented at the NCDEU Annual Meeting. Boca Raton, Florida, May 29 - June 1, 2000.

  40. David S, Morgan M, Cook IA, Babaie A, Lightner A, Thomas S, Broumandi D, Mody R, Aroya S, Zheng Z, Leuchter AF: Regional changes in cerebral tissue volume in normal aging.  Poster presented at the UCLA Research Conference on Aging.  Los Angeles, California, June 21, 2000.

  41. Leuchter AF, Cook IA, Witte EA, Abrams M:  Brain Functional and Structural Differences between Medication and Placebo Responders.  Poster presented at the 11th Biennial Congress on Pharmaco-EEG, International Pharmaco-EEG Society, Vienna, Austria, September 1-3, 2000.

  42. Cook IA, Leuchter AF, Witte E, Stubbeman WF.  Prefrontal changes predict speed and completeness of antidepressant response.  Poster presented at the 11th Biennial Congress on Pharmaco-EEG, International Pharmaco-EEG Society, Vienna, Austria, September 1-3, 2000.

  43. Krell HV, Cook IA, Abrams M, Hanson K, Tolbert T, Leuchter AF.  Reboxetine Yields Symptomatic and Functional Improvement in Unipolar Depression.  Poster presented at the NCDEU Annual Meeting.  Phoenix, Arizona, May 28-31,2001.

  44. Cook IA, Leuchter AF, Morgan M, David S, Dunkin J, Lufkin R.  Subclinical Structural Brian Disease: Longitudinal Progression in Normal Aging.  Poster presented at the NCDEU Annual Meeting.  Phoenix, Arizona, May 28-31,2001.

  45. Leuchter AF, Cook IA, Greenwald S, Morgan M, Hanson K, Siegman B.  Bispectral Index (BIS) Correlates With Dementia Severity in AD and VAD.  Poster presented at the American Psychiatric Association Annual Meeting, Philadelphia, PA, May 19-23, 2002.

  46. Morgan ML, VanBatenburg C, Cook IA, Leuchter AF, Rapkin A, Siegman  B, Mickes L. Serum estrogen levels in perimenopause, memory and mood. Poster presented at the American Psychiatric Association Annual Meeting. San Francisco, CA, May 17-22, 2003.

  47. Leuchter AF, DeBrota DJ, Cook IA, Morgan ML, Abrams MJ, Siegman B, Cohen J, Mickes L, Krell H, Potter WZ.  Physiologic assessment of antidepressant drug effects in normal and depressed subjects. Poster presented at the American Psychiatric Association Annual Meeting. San Francisco, CA, May 17-22, 2003.

  48. Krell H, Leuchter AF, Cook IA, Morgan ML, Abrams MJ.  Patient expectation as a predictor of outcome in antidepressant treatment. Poster presented at the American Psychiatric Association Annual Meeting. San Francisco, CA, May 17-22, 2003.

  49. Hunter AM, Leuchter AF, Morgan ML, Cook IA, DeBrota D, Potter WZ.  Brain function correlates of side effects in normal subjects randomized to venlafaxine versus placebo.  Poster presented at the American Psychiatric Association Annual Meeting. San Francisco, CA, May 17-22, 2003.

  50. Cook IA, Leuchter AF, Morgan ML, Abrams MJ.  Changes in QEEG cordance and treatment resistant depression.  Poster presented at the American Psychiatric Association Annual Meeting. San Francisco, CA, May 17-22, 2003.

  51. Cook IA, Leuchter AF, Greenwald SD, Morgan ML, Abrams MJ, Siegman B. QEEG cordance changes predict treatment response to reboxetine in major depression.  Poster presented at the American Psychiatric Association Annual Meeting. San Francisco, CA, May 17-22, 2003.

  52. Morgan ML, Van Batenburg C, Cook IA, Leuchter AF, Rapkin A, Siegman  B, Mickes L. Serum estrogen levels in perimenopause, memory and mood.  Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, May 27-30, 2003.

  53. Leuchter AF, DeBrota DJ, Cook IA, Morgan ML, Abrams MJ, Siegman B, Cohen J, Mickes L, Krell H, Potter WZ.  Physiologic assessment of  antidepressant drug effects in normal and depressed subjects.  Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, May
    27-30, 2003.

  54. Krell H, Leuchter AF, Cook IA, Morgan ML, Abrams MJ.  Patient expectation as a predictor of outcome in antidepressant treatment. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, May 27-30, 2003.

  55. Cook IA Leuchter AF, Greenwald SD, Morgan ML, Abram MJ, Siegman B.  Changes in QEEG cordance predict response in treatment resistant depression and in reboxetine monotherapy.   Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, May 27-30, 2003.

  56. Wagner-Steh K, Dunkin JJ, Leuchter AF, Cook IA, David S, Kasl-Godley J, Abrams M.  Interaction of age and depression on cognitive functioning.  Poster presented at the UCLA Aging Conference.  Los Angeles, CA, June 25, 2003.

  57. Leuchter AF.  Dual-action antidepressants: the new frontier for treatment for co morbid depression.  Psychiatry in Clinical Practice 4:300 2003.

  58. Leuchter AF, Cook IA, Greenwald SD, Kofol T.  Prefrontal EEG Cordance Correlates with Anterior Cingulate Perfusion.  Poster presented at the New Research session, American Psychiatric Association Annual Meeting.  New York, New York, May 1-6, 2004.

  59. Cook IA, Leuchter AF, Morgan ML, Mickes L, Siegman B.  Drug Sensitivity and Periventricular Hyperintensities in the Aging Brain.  Poster presented at the American Psychiatric Association Annual Meeting.  New York, New York, May 1-6, 2004.

  60. Leuchter AF, Morgan ML, Cook IA, Greenwald SD, Devlin P.  Prospective Evaluation of a Model for Identification of Placebo Responders Prior to Randomization in Treatment Trials for MDD.  Poster presented at the NCDEU Annual Meeting.  Phoenix, Arizona, June 1-4, 2004.

  61. Cook IA, Leuchter AF, Morgan ML, Abrams MJ, Mickes L, Siegman B.  Drug Sensitivity in the Aging Brain and Periventricular Hyperintensities.  Poster presented at NCDEU Annual Meeting.  Phoenix, Arizona, June 1-4, 2004.

  62. Hunter AM, Leuchter AF, Cook IA, Morgan ML.  Changes in brain function during placebo lead-in and treatment outcome in clinical trials for major depression.  Poster presented at the NCDEU Annual Meeting.  Phoenix, Arizona, June 1-4, 2004

  63. Leuchter AF, Cook IA, Hunter A, Morgan ML, McGrouther C, Abrams M.  Functional Changes in the Brain Associated with Clinical Response to Duloxetine.  Poster presented at the XXIV CINP 2004 Congress.  Paris, France, June 20-24, 2004.

  64. Leuchter AF.  Are Serotonin and Norepinephrine the Key to Complete Symptom Resolution?  Journal of Psychosomatic Research 56: 581-673, 2004.

  65. Leuchter AF, Cook IA, Hunter AM, Morgan ML, McGrouther C, Abrams M. Functional Changes in the Brain Associated with Remission in Major Depressive Disorder. Poster presented at the SOBP Annual Meeting. Atlanta, Georgia, May 19-21, 2005.

  66. Leuchter AF, Kofol T, Greenwald SD, Devlin P, Cook IA. Source Localization of Anterior Cingulate Activity: Comparison of 4 Versus 24 Channel EEG Techniques. Poster presented at the APA Annual Meeting. Atlanta, Georgia, May 21-26, 2005.

  67. Cook IA, Shapiro D, Leuchter AF, Abrams M, Ottaviani C. Yoga Augmentation and Remission in Partial Responders to Antidepressant Medications. Poster presented at the APA Annual Meeting, Atlanta, Georgia, May 21-26, 2005.

  68. Morgan ML, Cook IA, Rapkin AJ, Leuchter AF. Brain Function and Estrogen Augmentation in Perimenopausal Depression. Poster presented at the NCDEU Annual Meeting, Boca Raton, Florida, June 6-10, 2005.

  69. Cook IA, Shapiro D, Leuchter AF, Abrams M, Ottaviani C. Yoga Augmentation and Remission in Partial Responders to Antidepressant Medications. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, June 6-9, 2005.

  70. Cook IA, Hunter AM, Abrams M, Siegman B, Leuchter AF. Midline and Right Frontal Brain Function and Remission in Major Depression. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, June 12-15, 2006.

  71. Morgan ML, Rapkin A, Rasgon NL, Cook IA, Leuchter AF. Neuroactive Steroids, Estrogen, and Sertraline in Menopausal Depression. Poster presented at the NCDEU Annual Meeting. Boca Raton, FL, June 12-15, 2006.

  72. Leuchter AF, Cook IA, Siegman B, Kofol T, Greenwald SD, Devlin P. EEG Antidepressant Response Index Correlates with Anterior Cingulate Perfusion in Normal Subjects. Poster presented at the EEG and Clinical Neuroscience Society (ECNS) Annual Meeting. Boston, MA, September 13-17, 2006.